Dogwood Therapeutics, Inc. insider trading

Every open-market purchase and sale by Dogwood Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Dogwood Therapeutics, Inc.’s insiders pay?

From February 1, 2021 to August 22, 2023, 5 insiders reported 14 open-market purchases and 0 sales not made under a pre-set plan in Dogwood Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −70.9% against the S&P 500 on average (median −79.7%), over 10 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 2, 2021 into $664 by November 2, 2026, −37.7% a year. It held shares 37% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,692 (+4.3% a year), and held throughout $21,405 (+14.2%).

Copying Dogwood Therapeutics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Dogwood Therapeutics, Inc.'s insiders from February 2, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 37% of the time.

Dogwood Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Pridgen William	Director	7	−70.1% (5)	0%	—	August 22, 2023
Duncan Gregory Scott	CHIEF EXECUTIVE OFFICER	4	−57.8% (2)	0%	—	August 18, 2023
De La Rosa Abel	Director	1	−81.6% (1)	0%	—	January 7, 2022
Keefer David R	Director	1	−79.9% (1)	0%	—	January 5, 2022
Whitley Richard James	Director	1	−81.6% (1)	0%	—	January 7, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Dogwood Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Dogwood Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −15.0% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
December 31, 2021	2 buying	−6.9%	−0.9%	−76.8%
April 30, 2021	2 buying	+4.6%	−29.2%	−25.9%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Dogwood Therapeutics, Inc. · Funds · Politicians